Mesoblast Limited
MSB.ASXHealth Care
A biotechnology company in the area of adult stem cell technology.
Market Data
$2.225
-0.0%$3.0B
-100000.0x
$-0.105
0.00%
-0.1%
Latest Earnings
Half Year Report and Accounts (including Appendix 4D)
27 February 2026
Mesoblast achieved a significant inflection point with Ryoncil® product sales of $48.7M in the first six months following its late-March 2025 commercial launch, though the company recorded a net loss of $40.2M (vs $47.9M loss in pcp) on total revenues of $51.3M. The company secured $75M from a new $125M non-dilutive credit facility and maintains $130M in cash, providing runway to fund operations and continued commercialization despite elevated R&D and SG&A spend. Key points: Ryoncil® launched commercially in late March 2025 with $48.7M in product sales captured in just 3 months of the half-year period, demonstrating strong market acceptance; Net loss improved 16.3% to $40.2M vs $47.9M in pcp, with gross margin of 85.2% showing strong product economics; Secured $75M drawn from a new $125M non-dilutive credit facility with favourable terms; second $50M tranche available through June 2026
Recent Announcements
Ceasing to be a substantial holder
State Street Corporation ceased to be a substantial holder.
Ceasing to be a substantial holder
JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.
Becoming a substantial holder
JPMorgan Chase & Co. and its affiliates became a substantial holder (5.40%).
Ceasing to be a substantial holder
JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.
Becoming a substantial holder
JPMorgan Chase & Co. and its affiliates became a substantial holder (5.04%).
Ceasing to be a substantial holder
JPMorgan Chase & Co. and its affiliates ceased to be a substantial holder.
Becoming a substantial holder
State Street Corporation became a substantial holder (5.19%).
Corporate Presentation and Half Year Financial Results
Mesoblast Limited (ASX: MSB; Nasdaq: MESO) reported H1 FY26 financial results showing RYONCIL net revenue of US$49M following FDA approval in December 2024, with guidance of US$110-120M for full-year FY2026; the company maintains a strong cash position of US$130M and is advancing clinical programs for label expansions and second-generation products including rexlemestrocel-L.
Half Year Report and Accounts (including Appendix 4D)
Mesoblast achieved a significant inflection point with Ryoncil® product sales of $48.7M in the first six months following its late-March 2025 commercial launch, though the company recorded a net loss of $40.2M (vs $47.9M loss in pcp) on total revenues of $51.3M. The company secured $75M from a new $125M non-dilutive credit facility and maintains $130M in cash, providing runway to fund operations and continued commercialization despite elevated R&D and SG&A spend. Key points: Ryoncil® launched commercially in late March 2025 with $48.7M in product sales captured in just 3 months of the half-year period, demonstrating strong market acceptance; Net loss improved 16.3% to $40.2M vs $47.9M in pcp, with gross margin of 85.2% showing strong product economics; Secured $75M drawn from a new $125M non-dilutive credit facility with favourable terms; second $50M tranche available through June 2026
Earnings Release - 26 February 2026
Upcoming earnings release expected 26 February 2026 (from Yahoo Finance (confirmed))
Get real-time alerts for MSB
Receive AI-powered earnings summaries and instant notifications when Mesoblast Limited releases results.
Register Free